Immuneering CorpIMRXEarnings & Financial Report
Nasdaq
IMRX Q4 2023 Key Financial Metrics
Revenue
$0
Gross Profit
$0
Operating Profit
$-16.3M
Net Profit
$-15.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.51
Immuneering Corp Q4 2023 Financial Summary
Immuneering Corp reported revenue of $0 for Q4 2023, with a net profit of $-15.1M (N/A margin). Cost of goods sold was $0, operating expenses totaled $16.3M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-15.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 2023 |
Immuneering Corp Annual Revenue by Year
Immuneering Corp annual revenue history includes year-by-year totals (for example, 2023 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2023 | $0 |
| 2022 | $317.0K |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $183698 | $94419 | $38380 | $455 | $0 | $0 | $0 | $0 |
| YoY Growth | -75.4% | -85.7% | -92.0% | -99.8% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $152.4M | $142.0M | $133.7M | $122.4M | $107.7M | $124.9M | $113.9M | $102.6M |
| Liabilities | $8.4M | $8.5M | $11.8M | $12.5M | $9.9M | $9.8M | $9.9M | $12.0M |
| Equity | $144.1M | $133.6M | $121.9M | $109.9M | $97.8M | $115.1M | $104.0M | $90.6M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-12.3M | $-9.4M | $-10.6M | $-11.7M | $-14.4M | $-10.7M | $-12.0M | $-11.8M |